Number of lymph nodes associated with maximal reduction of long-term mortality risk in pathologic node-negative non-small cell lung cancer

Annals of Thoracic Surgery

Volumn 97, Issue 2, 2014, Pages 385-393

  Osarogiagbon, Raymond U ^a   Ogbata, Obiageli ^a   Yu, Xinhua ^b  

^a BAPTIST CANCER CENTER   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

Author keywords

10; CTSNet classification

Indexed keywords

10;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS;

EID: 84893358046     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2013.09.058     Document Type: Article

References (28)

1. A. Jemal, M.M. Center, and C. DeSantis et al. Global patterns of cancer incidence and mortality rates and trends Cancer Epidemiol Biomarkers Prev 19 2010 1893 1907
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
3. P. Goldstraw, J. Crowley, and K. Chansky et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumors J Thorac Oncol 2 2007 706 714
4. V.W. Rusch, J. Crowley, and D.J. Giroux et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer J Thorac Oncol 2 2007 603 612
5. A. Gajra, N. Newman, and G.P. Gamble et al. Effect of number of lymph nodes sampled on outcome of patients with stage I non-small-cell lung cancer J Clin Oncol 21 2003 1029 1034
6. F.C. Detterbeck, J. Puchelski, and A. Rubinowitz et al. Classification of the thoroughness of mediastinal staging of lung cancer Chest 137 2010 436 442
7. G.N. Gephardt, and P.B. Baker Lung carcinoma surgical pathology report adequacy Arch Pathol Lab Med 120 1996 922 927
8. A. Farooq, R.U. Osarogiagbon, and J.W. Allen et al. Accuracy and comprehensiveness of pathology reportage after lung cancer resection J Clin Oncol 27 2009 15s (suppl; abstr 6523)
9. R.U. Osarogiagbon, and X. Yu Mediastinal lymph node examination and survival in resected early stage non-small cell lung cancer in the surveillance, epidemiology and end results database J Thorac Oncol 7 2012 1798 1806
10. R.A. Ramirez, C.G. Wang, and L.E. Miller et al. Incomplete intrapulmonary lymph node retrieval after routine pathologic examination of resected lung cancer J Clin Oncol 30 2012 2823 2828
11. J.M. Varlotto, A. Recht, and M. Nikolov et al. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer Cancer 115 2009 851 858
12. S.I. Ou, and J.A. Zell Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer J Thorac Oncol 3 2008 880 886
13. R.U. Osarogiagbon, J.W. Allen, and A. Farooq et al. Outcome of surgical resection for pathologic N0 and Nx non-small cell lung cancer J Thorac Oncol 5 2010 191 196
14. R.U. Osarogiagbon, and X. Yu Nonexamination of lymph nodes and survival after resection of non-small cell lung cancer Ann Thorac Surg 96 2013 1178 1189
15. R.U. Osarogiagbon, R.A. Ramirez, and C. Wang et al. Survival analysis of patients with/without lymph node examination after lung cancer resection J Clin Oncol 29 2011 (suppl; abstr 7054)
16. National Cancer Institute. Surveillance Epidemiology and End Results. Overview of the SEER program. Available at: http://seer.cancer.gov/about/ overview.html. Accessed: November 6, 2012.
17. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
18. The International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
19. T. Winton, R. Livingston, and D. Johnson et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2005 2589 2597
20. J. Pignon, H. Tribodet, and G.V. Scagliotti et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group J Clin Oncol 26 2008 3552 3559
21. B.E. Lally, D. Zelterman, and J.M. Colasanto et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database J Clin Oncol 24 2006 2998 3006
22. Y. Wu, C.J. Lin, and W. Hsu et al. Long-term results of pathological stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control Eur J Cardiothorac Surg 24 2003 994 1001
23. M.S. Ludwig, M. Goodman, and D.L. Miller et al. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer Chest 128 2005 1545 1550
24. A.N.J. Graham, K.J.M. Chan, U. Pastorino, and P. Goldstraw Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer J Thorac Cardiovasc Surg 117 1999 246 251
25. M.S. Allen, G.E. Darling, and T.T.V. Pechet et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial Ann Thorac Surg 81 2006 1013 1020
26. G.E. Darling, M.S. Allen, and P.A. Decker et al. Number of lymph nodes harvested from a mediastinal lymphadenectomy Chest 139 2011 1124 1129
27. G.E. Darling, M.S. Allen, and P.A. Decker et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 trial J Thorac Cardiovasc Surg 141 2011 661 670
28. R.U. Osarogiagbon, J.W. Allen, and A. Farooq et al. Objective review of mediastinal lymph node examination in a lung cancer resection cohort J Thorac Oncol 7 2012 390 396